Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

Bullboard Posts

Comment by Hideawayon Aug 14, 2020 3:56pm

197 Views

Post# 31410421

RE:RE:RE:2questions and answered by IR

Reading Christina's responses, it looks as if we may be well into 2021 before any uplisting,which I totally agree with.The likelihood of an FDA meeting in 2020 also may be off until next year.Just wondering what will happen to the markets after the Nov. US election.If,and it appears likely according to polls,that Dems are the big winners,particularly in the intervening time between Nov. and the Jan. inauguration.I fear it will be a very caouthic time.How will the markets react,not well I expect.Plus the mess left over from the previous administration will also not bode well. If no big pharma deals happen for ate until 2021,where will this put our share price? Comments?

Bullboard Posts

Cannara reports record growth and profitability in Q4 2023